UCLA to Co-Lead a Large-Scale Randomized Trial of AI in Breast Cancer Screening

Large breast cancer screening trial will be pivotal step in vetting AI for mammograms

Millions of mammograms are scanned with AI every year. A new $16 million randomized controlled trial aims to test if the tech helps patients.

UCLA to co-lead a large-scale randomized trial of AI in breast cancer screening

UCLA and UC Davis will co-lead a newly funded, multi-institutional clinical trial to evaluate whether artificial intelligence (AI) can help support radiologists in interpreting mammograms more accurately, with the goal of improving breast cancer screening and reducing unnecessary callbacks and anxiety for patients.

ScreenPoint Medical's Transpara® Breast AI Selected for $16M PRISM Randomized Controlled Trial in USA

NEW YORK and NIJMEGEN, Netherlands, Sept. 23, 2025 /PRNewswire/ -- ScreenPoint Medical today announced that its Transpara® breast imaging AI solution has been selected as the technology of choice for the PRISM (Pragmatic Randomized Trial of Artificial Intelligence for Screening…

UCLA to spearhead $16 Million National Research Initiative on AI in Breast

UCLA and UC Davis are embarking on a groundbreaking research initiative that could reshape the landscape of breast cancer screening in the United States. Funded by a substantial $16 million grant from the Patient-Centered Outcomes Research Institute (PCORI), the PRISM Trial (Pragmatic Randomized Trial of Artificial Intelligence for Screening Mammography) is set to investigate the […]